- 25371 Commercentre Dr, Lake Forest, CA 92630
- Patients Results
GTC combines advanced genomic testing with artificial intelligence, machine learning, and scalable interpretation tools to help transform complex molecular data into clinically meaningful insight. Our technology innovation strategy is designed to support faster interpretation, broader molecular understanding, and more practical use of genomic information in precision oncology.
GTC applies artificial intelligence to help organize, review, and interpret complex genomic data more efficiently. This technology-driven approach supports the evaluation of molecular alterations in ways that can help inform diagnosis, prognosis, and therapeutic decision-making in oncology.
Each result contributes to a growing body of genomic knowledge, helping refine interpretation and support continuous learning. By using machine learning to review alterations and track their frequency, GTC is positioned to generate deeper insights over time and strengthen the clinical value of molecular testing.
Technology innovation at GTC is not presented as research alone, but as a practical extension of patient care. The goal is to help clinicians move from complex genomic findings to clearer, more usable information that can support precision medicine in real-world workflows. This physician-facing emphasis is reflected in the current page’s focus on interpretation, reporting, and practical application.
The current page specifically highlights Interprestation™ as a tool developed to simplify a difficult part of NGS testing. Positioned within the broader AI and machine learning framework, it reflects GTC’s effort to convert advanced interpretation technology into a more accessible and clinically useful experience for customers.
GTC uses artificial intelligence to help sort through and curate large sets of genomic data so that clinically relevant alterations can be reviewed more efficiently. The purpose is not simply automation, but improved interpretation of complex molecular findings in support of diagnosis, prognosis, and therapeutic assessment.
Machine learning allows genomic findings to be reviewed continuously as additional results are added to a growing knowledge base. By tracking alterations and their frequency over time, machine learning can help strengthen interpretation, improve pattern recognition, and contribute to a more informed understanding of cancer biology.
One of the main challenges in modern molecular oncology is not only generating genomic data, but making that data clinically usable. Technology innovation helps reduce the burden of interpreting complex results by supporting a more efficient pathway from molecular findings to clinically meaningful insight. For physicians, that means clearer information that can be more readily incorporated into patient care decisions.
GTC’s innovation model combines advanced genomic testing with interpretation tools designed to help contextualize alterations within oncology care. Rather than treating molecular data as an isolated output, the goal is to organize and interpret findings in a way that helps support treatment planning, clinical relevance, and precision medicine strategy. This is consistent with the current page’s emphasis on assessing impact on diagnosis, prognosis, and response to therapy.
Interprestation™ is presented by GTC as part of its technology innovation strategy and is specifically described as a way to simplify the hard part of NGS testing. In practice, its role is to make interpretation more accessible by supporting the review of complex genomic information through AI-assisted workflows.
Precision oncology depends on the ability to translate broad molecular findings into usable clinical insight. GTC’s approach to technology innovation is designed to support that translation by combining genomic testing, AI, machine learning, and interpretation infrastructure into a more connected system for molecular decision support.
At GTC, technology innovation is focused on making complex genomic information more useful in clinical practice. By combining artificial intelligence, machine learning, interpretation tools, and an expanding genomic knowledge base, GTC aims to support a more efficient, more informed, and more clinically relevant approach to precision oncology.
Learn how GTC’s genomic testing solutions use AI & Machine Learning to support comprehensive molecular profiling across solid tumors, hematologic malignancies, and liquid biopsy applications.
